Cesca Therapeutics Inc. (NASDAQ:KOOL) has been assigned an average broker rating score of 3.00 (Hold) from the one brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation.

Zacks has also given Cesca Therapeutics an industry rank of 171 out of 265 based on the ratings given to its competitors.

Separately, ValuEngine cut shares of Cesca Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th.

Shares of Cesca Therapeutics (NASDAQ KOOL) opened at $2.94 on Friday. The company has a quick ratio of 1.23, a current ratio of 2.06 and a debt-to-equity ratio of 0.16. Cesca Therapeutics has a fifty-two week low of $2.41 and a fifty-two week high of $6.44.

TRADEMARK VIOLATION NOTICE: “Zacks: Cesca Therapeutics Inc. (KOOL) Receives Average Rating of “Hold” from Analysts” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/12/03/zacks-cesca-therapeutics-inc-kool-receives-average-rating-of-hold-from-analysts.html.

About Cesca Therapeutics

Cesca Therapeutics Inc is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.

Get a free copy of the Zacks research report on Cesca Therapeutics (KOOL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cesca Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.